Theravance Biopharma TBPH 深 沪
等待开盘 10-18 09:30:00 美东时间
14.335
+0.295
+2.10%
华盛通- 最 高14.335
- 今 开14.00
- 成交量 21.91万股
- 最 低 13.96
- 昨 收 14.04
- 总市值 7.22亿
- 52周最高 15.15
- 市盈率 静 --
- 换手率 0.43%
- 52周最低 7.90
- 委 比 13.12%
- 总股本 5036.13万
- 历史最高 43.44
- 量 比 0.86
- 振 幅 2.67%
- 历史最低 6.10
- 每 手 1
- 风险率 1.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Theravance Biopharma Will Be Presenting At CHEST 2025, The Annual Meeting Of The American College Of Chest Physicians
A retrospective cohort study of claims data demonstrated that following hospital discharge, patients adherent to YUPELRI experienced significantly fewer, and less severe, exacerbations and had significantly lower
10-14 18:05
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
B. Riley Securities Initiates Coverage On Theravance Biopharma with Buy Rating, Announces Price Target of $28
B. Riley Securities analyst Mayank Mamtani initiates coverage on Theravance Biopharma (NASDAQ:TBPH) with a Buy rating and announces Price Target of $28.
09-12 17:33
Theravance Biopharma Completes Enrollment In Pivotal Phase 3 Trial For Blood Pressure Disorder, Advances Phase 3 CYPRESS Study Targeting Rare Neurodegenerative Disease Affecting MSA Patients
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH), today announced completion of enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study in patients with
08-25 18:05
Here are the major earnings after the close Tuesday
Major earnings expected after the bell on Tuesday include: CoreWeave (CRWV) Inovio Pharmaceuticals (INO) Luminar Technologies (LAZR) Lumentum Holdings (LITE) Gladstone Investment Corporation (GAIN) Ot...
08-12 22:00
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025
DUBLIN, July 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2025 financial results and provide a business update after market close on Tues...
07-28 18:00
美股大行评级 | 潜在涨幅205.56%！康托·菲茨杰拉德上调HIVE Digital Technologies目标价至5.5美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德：维持HIVE Digital Technologies(HIVE)"超配"评级，目标价从5美元升至5.5美元</p> <p>• BTIG：维持Theravance Biopharma(TBPH)"买入"评
06-28 08:37
BTIG Maintains Buy on Theravance Biopharma, Raises Price Target to $25
BTIG analyst Julian Harrison maintains Theravance Biopharma (NASDAQ:TBPH) with a Buy and raises the price target from $24 to $25.
06-27 22:58
Theravance Biopharma Gains Milestone Payment from Viatris
Theravance Biopharma ( ($TBPH) ) has provided an announcement. On June 26, 2025...
06-26 18:28
